Karen A Veverka

This inventor holds 15 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 7 EPO patents. Top assignees: The University of Tennessee Research Foundation, Gtx Corporation, Otx, Inc.. Active years: 2005-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karen A Veverka. Retrieved from https://idiyas.com/inventor/karen-a-veverka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 1)

% Patents Active = 6.7

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 3.2

ph-index = 11

Forward Citations = 391(Granted Patents)

Company Filing History:

11 out of 788

The University of Tennessee Research Foundation

Years Active: 2005-2012

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8088828 - Treating benign prostate hyperplasia with SARMS (2012-01-03),

2. 8008348 - Treating muscle wasting with selective androgen receptor modulators (2011-08-30),

3. 8003689 - Metabolites of selective androgen receptor modulators and methods of use thereof (2011-08-23),

4. 7968721 - Large-scale synthesis of selective androgen receptor modulators (2011-06-28),

5. 7855229 - Treating wasting disorders with selective androgen receptor modulators (2010-12-21),

6. 7803970 - Multi-substitued selective androgen receptor modulators and methods of use thereof (2010-09-28),

7. 7776921 - Treating benign prostate hyperplasia with SARMS (2010-08-17),

8. 7705182 - Multi-substituted selective androgen receptor modulators and methods of use thereof (2010-04-27),

9. 7622503 - Selective androgen receptor modulators and methods of use thereof (2009-11-24),

10. 7595402 - Prodrugs of selective androgen receptor modulators and methods of use thereof (2009-09-29),

11. 7547728 - Treating muscle wasting with selective androgen receptor modulators (2009-06-16),

12. 7524866 - Prevention and treatment of androgen—deprivation induced osteoporosis (2009-04-28),

13. 7026500 - Halogenated selective androgen receptor modulators and methods of use thereof (2006-04-11),

14. 6899888 - Prevention and treatment of androgen-deprivation induced osteoporosis (2005-05-31),

15. 6838484 - Formulations comprising selective androgen receptor modulators (2005-01-04),

Title: The Innovative Contributions of Karen A Veverka

Introduction

Karen A Veverka is a distinguished inventor based in Cordova, TN, USA, known for her significant contributions to the field of medicine. With a remarkable portfolio of 15 patents, her work primarily focuses on innovative treatments involving selective androgen receptor modulators (SARMs).

Latest Patents

Among her notable inventions, Karen's latest patents include methods for treating benign prostate hyperplasia and addressing muscle wasting disorders. The invention concerning benign prostate hyperplasia details a method to treat and reduce the incidence of this condition in male subjects by administering SARMs and their various derivatives. Additionally, she has developed methods for treating hair loss and inhibiting 5-alpha reductase enzymes, which involves similar SARM administration strategies. Another significant patent focuses on combating muscle wasting disorders, providing comprehensive methods for treatment and prevention by employing SARMs and their analogs.

Career Highlights

Throughout her career, Karen has collaborated with reputable organizations such as the University of Tennessee Research Foundation and GTX Corporation. Her work exemplifies a blend of research and practical application, allowing her to contribute meaningfully to advancements in medical science.

Collaborations

Karen has worked alongside respected professionals in her field, including Mitchell S. Steiner and Duane Douglas Miller. These collaborations have undoubtedly enriched her research and facilitated the development of groundbreaking innovations that hold promise for many patients suffering from debilitating conditions.

Conclusion

Karen A Veverka’s inventive spirit and dedication to advancing medical treatments set her apart as a significant figure in her field. Her numerous patents reflect her commitment to improving the quality of life for individuals facing various health challenges. As she continues her journey in innovation, the medical community eagerly anticipates her future contributions.

Profile summary based on public USPTO records.